| pubmed-article:12749901 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12749901 | lifeskim:mentions | umls-concept:C0037657 | lld:lifeskim |
| pubmed-article:12749901 | lifeskim:mentions | umls-concept:C0074825 | lld:lifeskim |
| pubmed-article:12749901 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
| pubmed-article:12749901 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:12749901 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:12749901 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:12749901 | pubmed:dateCreated | 2003-5-16 | lld:pubmed |
| pubmed-article:12749901 | pubmed:abstractText | 4-benzylquinolines 5, based on a series of isoquinolines 1, were prepared and tested as inhibitors of the IGF/IGFBP-3 complex based on their ability to displace IGF-I from its binding to IGF-binding protein-3. SAR studies on the 6,7-dihydroxy moiety of the quinoline 5a showed that the catecol moiety could be replaced with other functional groups. Computational modeling of the 5a/mini-IGFBP-5 complex revealed the possible binding site of 5a on IGFBP-5. | lld:pubmed |
| pubmed-article:12749901 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12749901 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749901 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12749901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749901 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12749901 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:12749901 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:YewP RPR | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:XXX | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:ZhuYun-FeiYF | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:GaoYinghongY | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:WilcoxenKeith... | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:LingNicholasN | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:McCarthyJames... | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:GrossTimothyT | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:ConnorsPatric... | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:StrackNathali... | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:GrossRaymondR | lld:pubmed |
| pubmed-article:12749901 | pubmed:author | pubmed-author:WangXiao-Chua... | lld:pubmed |
| pubmed-article:12749901 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12749901 | pubmed:day | 2 | lld:pubmed |
| pubmed-article:12749901 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:12749901 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12749901 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12749901 | pubmed:pagination | 1931-4 | lld:pubmed |
| pubmed-article:12749901 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:meshHeading | pubmed-meshheading:12749901... | lld:pubmed |
| pubmed-article:12749901 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12749901 | pubmed:articleTitle | Quinoline-carboxylic acids are potent inhibitors that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. | lld:pubmed |
| pubmed-article:12749901 | pubmed:affiliation | Neurocrine Biosciences, Inc., 10555 Science Center Drive, San Diego, CA 92121, USA. | lld:pubmed |
| pubmed-article:12749901 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:12749901 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12749901 | lld:pubmed |
